ANIK Anika Therapeutics, Inc.
Healthcare$14.89+0.07%ClosedMarket Cap: $198.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.50
P/S
1.70
EV/EBITDA
-27.56
DCF Value
$4.65
FCF Yield
0.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
58.6%
Operating Margin
-10.5%
Net Margin
-9.5%
ROE
-7.7%
ROA
-6.2%
ROIC
-7.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $29.6M | 64.2% | $-5.5M | $-5.1M | $— | — |
| Q4 null | $30.6M | 62.6% | $646.0K | $292.0K | $— | — |
| FY null | $112.8M | 56.6% | $-11.1M | $-10.9M | $— | — |
| Q3 null | $27.8M | 56.0% | $-3.2M | $-2.3M | $— | — |
| Q2 null | $28.2M | 50.9% | $-4.2M | $-4.0M | $— | — |
| Q1 null | $26.2M | 56.1% | $-4.3M | $-4.9M | $— | — |
| Q4 null | $-1.3M | -1749.2% | $27.8M | $-21.9M | $— | — |
| FY null | $119.9M | 63.4% | $-5.1M | $-56.4M | $— | — |
| Q3 null | $38.8M | 3.7% | $-28.0M | $-29.9M | $— | — |
| Q2 null | $30.7M | 66.7% | $-1.8M | $-88.0K | $— | — |
| Q1 null | $40.5M | 60.8% | $-5.1M | $-4.5M | $— | — |
| Q4 2023 | $43.0M | 61.3% | $-63.8M | $-63.0M | $-4.30 | — |